ISIN | LU2208649280 |
---|---|
Valor Number | 56107579 |
Bloomberg Global ID | UBSEBQL LX |
Fund Name | UBS (Lux) Equity Fund - Biotech (USD) QL-acc |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
Basel, Switzerland Phone: +41 61 288 75 01 E-Mail: sh-ubs-funds-feedback@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS Global Asset Management Basel Phone: +41 61 288 20 20 |
Asset Class | Equities |
EFC Category | Equity Global Advanced Markets |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations. |
Peculiarities |
Current Price * | 101.00 USD | 14.11.2024 |
---|---|---|
Previous Price * | 103.65 USD | 13.11.2024 |
52 Week High * | 113.07 USD | 29.07.2024 |
52 Week Low * | 86.47 USD | 16.11.2023 |
NAV * | 101.00 USD | 14.11.2024 |
Issue Price * | 101.00 USD | 14.11.2024 |
Redemption Price * | 101.00 USD | 14.11.2024 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 438,965,977 | |
Unit/Share Assets *** | 24,419,395 | |
Trading Information SIX |
YTD Performance | -1.76% |
29.12.2023 - 14.11.2024
29.12.2023 14.11.2024 |
---|---|---|
YTD Performance (in CHF) | +3.92% |
29.12.2023 - 14.11.2024
29.12.2023 14.11.2024 |
1 month | -4.28% |
14.10.2024 - 14.11.2024
14.10.2024 14.11.2024 |
3 months | -4.82% |
14.08.2024 - 14.11.2024
14.08.2024 14.11.2024 |
6 months | +0.76% |
14.05.2024 - 14.11.2024
14.05.2024 14.11.2024 |
1 year | +15.35% |
14.11.2023 - 14.11.2024
14.11.2023 14.11.2024 |
2 years | -2.58% |
14.11.2022 - 14.11.2024
14.11.2022 14.11.2024 |
3 years | -5.38% |
15.11.2021 - 14.11.2024
15.11.2021 14.11.2024 |
5 years | +1.00% |
15.09.2020 - 14.11.2024
15.09.2020 14.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Vertex Pharmaceuticals Inc | 10.09% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 7.33% | |
Neurocrine Biosciences Inc | 5.12% | |
Moderna Inc | 4.90% | |
Amgen Inc | 4.85% | |
Regeneron Pharmaceuticals Inc | 4.76% | |
AbbVie Inc | 4.25% | |
Denali Therapeutics Inc | 3.85% | |
Biohaven Ltd | 3.50% | |
Guardant Health Inc | 3.34% | |
Last data update | 31.10.2024 |
TER | 0.88% |
---|---|
TER date | 30.11.2023 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.66% |
Ongoing Charges *** | 0.89% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |